New HIV vaccine approach combines nanoparticles and mRNA in first human test
NCT ID NCT05903339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new HIV vaccine strategy in 36 healthy adults without HIV. The vaccine uses ferritin nanoparticles to display HIV envelope proteins, followed by an mRNA boost. The goal is to safely trigger broadly neutralizing antibodies that could protect against many HIV strains. The study focuses on safety and immune response, not prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ferritin nanoparticles with HIV envelope trimers and mRNA lipid nanoparticles
What this could lead to
If successful, this could point toward a vaccine that teaches the immune system to make broadly neutralizing antibodies against HIV, a major step toward preventing infection.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, so it primarily tests safety and immune response, not effectiveness. Many promising vaccine candidates fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS [Site ID: 31788]
Birmingham, Alabama, 35294-2170, United States
-
BIDMC VCRS [Site ID: 32077]
Boston, Massachusetts, 02215, United States
-
Brigham & Women's Hospital [Site ID: 30007]
Boston, Massachusetts, 02115, United States
-
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802]
Atlanta, Georgia, 30303, United States
-
Seattle Vaccine and Prevention CRS [Site ID: 30331]
Seattle, Washington, 98104, United States
-
Vanderbilt Vaccine (VV) CRS [Site ID: 30352]
Nashville, Tennessee, 37232-2582, United States